Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.61 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.48 |
| ▸ | NOTUM | Q6P988 | 5/20 | 0.48 |
| ▸ | DHODH | Q02127 | 1/20 | 0.46 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.44 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MPO | P05164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3653863 | 0.92 | ESR2 (0.55) | ESR2BRD4PDK1PDK2PDK3 | |
| SCHEMBL30674388 | 0.92 | ESR2 (0.55) | ESR2BRD4PDK1PDK2PDK3 | |
| SCHEMBL3902752 | 0.89 | ESR2 (0.50) | ESR2GPR119NOTUMDHODHBRD4 | |
| SCHEMBL3905057 | 0.89 | ESR2 (0.61) | ESR2GPR119NOTUMDHODHPDK1 | |
| SCHEMBL27975558 | 0.87 | NOTUM (0.65) | ESR2GPR119NOTUMDHODHABHD6 | |
| SCHEMBL8200750 | 0.86 | NOTUM (0.64) | ESR2GPR119NOTUMDHODHABHD6 | |
| SCHEMBL760643 | 0.84 | ABHD6 (0.63) | ESR2GPR119NOTUMDHODHABHD6 | |
| SCHEMBL2005945 | 0.84 | GPR119 (0.47) | ESR2GPR119NOTUMDHODHABHD6 | |
| SCHEMBL8269763 | 0.84 | GPR119 (0.47) | ESR2GPR119NOTUMDHODHABHD6 | |
| SCHEMBL30147443 | 0.84 | NOTUM (0.65) | ESR2GPR119NOTUMDHODHABHD6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12391666-B2 | Indoline-1-formamide compound, preparation method therefor, and medical use thereof | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2025-08-19 | — | — | US | disclosed |
| CN-112543764-B | Amide compound with BET proteolytic induction effect and medical application thereof | 田边三菱制药株式会社 | 2024-05-10 | — | — | CN | disclosed |
| US-20230382893-A1 | AMIDE DERIVATIVE HAVING ANTIVIRAL ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2023-11-30 | — | — | US | disclosed |
| US-20230382893-A1 | AMIDE DERIVATIVE HAVING ANTIVIRAL ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2023-11-30 | — | — | US | disclosed |
| CN-112384506-B | Indoline-1-formamide compound, preparation method and application thereof in medicine and pharmacology | 北京诺诚健华医药科技有限公司 | 2023-01-24 | — | — | CN | disclosed |
| US-20210188806-A1 | INDOLINE-1-FORMAMIDE COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2021-06-24 | — | — | US | disclosed |
| US-20210188806-A1 | INDOLINE-1-FORMAMIDE COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2021-06-24 | — | — | US | disclosed |
| EP-3795567-A1 | INDOLINE-1-FORMAMIDE COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | Beijing InnoCare Pharma Tech Co., Ltd. (CN) | 2021-03-24 | — | — | EP | disclosed |
| EP-3795567-A1 | INDOLINE-1-FORMAMIDE COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | Beijing InnoCare Pharma Tech Co., Ltd. (CN) | 2021-03-24 | — | — | EP | disclosed |
| CN-112543764-A | Amide compound with BET proteolysis induction effect and medical application thereof | 田边三菱制药株式会社 | 2021-03-23 | — | — | CN | disclosed |
| EP-1553097-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AND INTERMEDIATES THEREFORE | AstraZeneca AB (SE) | 2005-07-13 | — | — | EP | disclosed |
| EP-1154774-B1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2005-06-22 | — | — | EP | disclosed |
| US-20050020624-A1 | Dihydroindole and tetrahydroquinoline derivatives | AEBI JOHANNES (CH) | 2005-01-27 | — | — | US | disclosed |
| WO-2004026837-A2 | HISTAMINE H3 RECEPTOR ANTAGONISTS, PREPARATON AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2004-04-01 | — | — | WO | disclosed |
| US-6706751-B2 | ANTICHOLESTEROL AGENTS; CARDIOVASCULAR DISORDERS; ANTIDIABETIC AGENTS; ANTIPROLIFERATIVE AGENTS | HOFFMAN-LA ROCHE INC. | 2004-03-16 | — | — | US | disclosed |
| EP-1358162-A1 | DIHYDROINDOLE AND TETRAHYDROQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-05 | — | — | EP | disclosed |
| US-6503907-B2 | Indole derivatives or dihydroindole derivatives or salts are useful for the treatment of diseases associated with 2,3-oxidosqualene-lanosterol cyclase such as gallstone, tumorhypercholesterolemia, hyperlipemia, arterioscerosis etc. | HOFFMANN-LA ROCHE INC. | 2003-01-07 | — | — | US | disclosed |
| US-20030004156-A1 | Dihydroindole and tetrahydroquinoline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2003-01-02 | — | — | US | disclosed |
| US-20020103247-A1 | Indole derivatives or dihydroindole derivatives or salts are useful for the treatment of diseases associated with 2,3-oxidosqualene-lanosterol cyclase such as gallstone, tumorhypercholesterolemia, hyperlipemia, arterioscerosis etc. | HOFFMANN-LA ROCHE INC. | 2002-08-01 | — | — | US | disclosed |
| WO-2002050041-A1 | DIHYDROINDOLE AND TETRAHYDROQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382893-A1 | AMIDE DERIVATIVE HAVING ANTIVIRAL ACTIVITY | ZC3HAV1, ZC3HAV1L, IFNAR1 | ESR2 1410/4885GPR119 581/4885NOTUM 517/4885 |
| US-12391666-B2 | Indoline-1-formamide compound, preparation method therefor, and medical use thereof | FLT1, KDR, TEK | ESR2 3569/4885GPR119 99/4885NOTUM 65/4885 |
| US-20050020624-A1 | Dihydroindole and tetrahydroquinoline derivatives | CYP46A1, LSS, CYP51A1 | ESR2 1642/4885GPR119 28/4885NOTUM 1315/4885 |
| US-20030004156-A1 | Dihydroindole and tetrahydroquinoline derivatives | CYP46A1, LSS, CYP51A1 | ESR2 1642/4885GPR119 28/4885NOTUM 1315/4885 |
| US-20020103247-A1 | Indole derivatives or dihydroindole derivatives or salts are useful for the treatment of diseases associated with 2,3-oxidosqualene-lanosterol cyclase such as gallstone, tumorhypercholesterolemia, hyperlipemia, arterioscerosis etc. | LSS, CYP51A1, DHCR7 | ESR2 2067/4885GPR119 15/4885NOTUM 1739/4885 |
| US-20210188806-A1 | INDOLINE-1-FORMAMIDE COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | FLT1, KDR, TEK | ESR2 3569/4885GPR119 99/4885NOTUM 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.